From GlobeNewswire: 2025-04-03 10:45:00

Bio-Convert, a subsidiary of Nordicus Partners Corporation, receives positive feedback from the Danish Medicine Agency for its lead drug candidate, QR-02, for oral leukoplakia treatment. DKMA’s feedback allows for a First in Human trial without animal studies. The gel formulation stays in the mouth for 12-24 hours, containing imiquimod as the active ingredient. The goal is to cure and reduce dysplasia levels in patients with oral leukoplakia. Bio-Convert aims to start the trial by the end of 2025. The unique drug delivery technology of QR-02 enhances precision and effectiveness in treatment. Nordicus Partners Corporation supports Nordic life sciences companies in the U.S. market and acquired both Orocidin A/S and Bio-Convert A/S.



Read more at GlobeNewswire: Bio-Convert Receives Positive Feedback from The Danish